Next Article in Journal
Clinical Determinants of Adrenal Vein Sampling Success
Previous Article in Journal
Copeptin for Early Diagnosis of Myocardial Infarction
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cardiovascular Medicine
Volume 18
Issue 9
10.4414/cvm.2015.00354
cardiovascmed-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Cardiovascular Medicine is published by MDPI from Volume 28 Issue 1 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Editores Medicorum Helveticorum (EMH).
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

PCSK9 Inhibitors: A New Era for Lipid-Targeted Therapies?

by
Isabella Sudano
1,*,
Arnold von Eckardstein
2,
Christian M. Matter
1,
Ulf Landmesser
3 and
Thomas F. Lüscher
1
1
Dept. of Cardiology, University Heart Centre, University Hospital of Zurich, Zurich, Switzerland
2
Institute of Clinical Chemistry, University Hospital of Zurich, Zurich, Switzerland
3
Cardiology Charité – University Berlin, Campus Benjamin Franklin, Franklin, Germany
*
Author to whom correspondence should be addressed.
Cardiovasc. Med. 2015, 18(9), 239; https://doi.org/10.4414/cvm.2015.00354
Submission received: 23 June 2015 / Revised: 23 July 2015 / Accepted: 23 August 2015 / Published: 23 September 2015
Versions Notes

Abstract

Mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) were first described in 2003 as a cause of autosomal dominant hypercholesterolaemia. Moreover, genetic studies have indicated that some PCSK9 lossoffunction mutations are associated with a markedly reduced risk of coronary artery disease (CAD), suggesting that PCSK9 represents a promising novel target for the prevention and management of CAD. Already, PCSK9 inhibition using monoclonal antibodies is entering the clinical management of familial hypercholesterolaemia and largescale clinical outcome programmes have been started to evaluate the impact of PCSK9 inhibition on cardiovascular events in highrisk patients. Both the refinement of monoclonal antibodybased therapies and the identification of this novel target represent an impressive example of the rapid translation of research to prevention of coronary disease, and may allow further reduction in lowdensity lipoprotein cholesterol levels to decrease progression or even reverse atherosclerosis.
Keywords: proprotein convertase subtilisin/kexin type 9; LDLcholesterol; cardiovascular risk proprotein convertase subtilisin/kexin type 9; LDLcholesterol; cardiovascular risk

Share and Cite

MDPI and ACS Style

Sudano, I.; von Eckardstein, A.; Matter, C.M.; Landmesser, U.; Lüscher, T.F. PCSK9 Inhibitors: A New Era for Lipid-Targeted Therapies? Cardiovasc. Med. 2015, 18, 239. https://doi.org/10.4414/cvm.2015.00354

AMA Style

Sudano I, von Eckardstein A, Matter CM, Landmesser U, Lüscher TF. PCSK9 Inhibitors: A New Era for Lipid-Targeted Therapies? Cardiovascular Medicine. 2015; 18(9):239. https://doi.org/10.4414/cvm.2015.00354

Chicago/Turabian Style

Sudano, Isabella, Arnold von Eckardstein, Christian M. Matter, Ulf Landmesser, and Thomas F. Lüscher. 2015. "PCSK9 Inhibitors: A New Era for Lipid-Targeted Therapies?" Cardiovascular Medicine 18, no. 9: 239. https://doi.org/10.4414/cvm.2015.00354

APA Style

Sudano, I., von Eckardstein, A., Matter, C. M., Landmesser, U., & Lüscher, T. F. (2015). PCSK9 Inhibitors: A New Era for Lipid-Targeted Therapies? Cardiovascular Medicine, 18(9), 239. https://doi.org/10.4414/cvm.2015.00354

Article Metrics

Back to TopTop